# Nuclide record urothelial-cancer (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/urothelial-cancer/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "urothelial-cancer" ;
  schema:name "Urothelial cancer"@en ;
  schema:alternateName "bladder cancer"@en, "transitional cell carcinoma"@en, "urothelial carcinoma"@en, "UC"@en ;
  schema:description "Urothelial cancer mostly starts in the bladder lining and ranges from tumours that stay superficial and are managed for years with local treatments to disease that spreads and needs systemic therapy. Survival depends heavily on how early it is caught, which is why so much attention goes into staging it accurately."@en ;
  schema:url <https://nuclide.cc/indications/urothelial-cancer/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://gco.iarc.who.int/media/globocan/factsheets/cancers/30-bladder-fact-sheet.pdf>, <https://seer.cancer.gov/statfacts/html/urinb.html>, <https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8057355/>, <https://www.mdpi.com/1424-8247/16/4/606> ;
  nuclide:tag "urological", "staging", "nodal-staging" ;
  nuclide:related <https://nuclide.cc/targets/nectin4/>, <https://nuclide.cc/technologies/fdg-pet/>, <https://nuclide.cc/technologies/immuno-pet/> ;
  nuclide:pipeline <https://nuclide.cc/opportunities/opp-nectin4-imaging-urothelial/>, <https://nuclide.cc/targets/nectin4/>, <https://nuclide.cc/technologies/fdg-pet/>, <https://nuclide.cc/technologies/immuno-pet/> .